Clinical trials in Ranica – page 87

2 668 clinical trials in Ranica, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Ranica at a glance

2 668

clinical trials

Research sites1

Quick filters

2 668 trials in Ranica

Open in trial search

Systemic scleroderma+2

Not yet recruiting

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anifrolumab
Sponsor:AstraZeneca AB

Contact Research Centre

Small cell lung cancer+2

Not yet recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:BioNTech SE

Contact Research Centre

Colorectal cancer metastatic

Not yet recruiting

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Genmab A/S

Contact Research Centre

Cardiovascular disorder+3

Not yet recruiting

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational

Italy

Participants:18–64 years
Substances:LY3841136 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Hypersomnia

Not yet recruiting

Phase 3 Randomized Double‑Blind Study of Pitolisant versus Placebo for Safety and Efficacy in Adults with Idiopathic Hypersomnia

Investigational

Phase 3 Randomized Double‑Blind Study of Pitolisant versus Placebo for Safety and Efficacy in Adults with Idiopathic Hypersomnia

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Pitolisant
Sponsor:Harmony Biosciences Management Inc.

Contact Research Centre

Chronic obstructive pulmonary disease

Not yet recruiting

Study of Two Doses of EXPD-101 vs Placebo for Reducing COPD Exacerbations in Adults with Chronic Obstructive Pulmonary Disease

Investigational

Study of Two Doses of EXPD-101 vs Placebo for Reducing COPD Exacerbations in Adults with Chronic Obstructive Pulmonary Disease

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:EXPD-101
Sponsor:Expedition Therapeutics Inc.

Contact Research Centre

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:REGN9933
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Pituitary-dependent Cushing's syndrome

Not yet recruiting

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Atumelnant
Sponsor:Crinetics Pharmaceuticals Inc.

Contact Research Centre

Type 2 diabetes mellitus

Not yet recruiting

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Insulin Glargine
Sponsor:Novo Nordisk A/S

Contact Research Centre

Type 2 diabetes mellitus

Not yet recruiting

Efficacy and Safety of Alogliptin Plus Empagliflozin Compared with Alogliptin Alone or Empagliflozin Alone in Adults with Type 2 Diabetes on Metformin

Registered drug

Efficacy and Safety of Alogliptin Plus Empagliflozin Compared with Alogliptin Alone or Empagliflozin Alone in Adults with Type 2 Diabetes on Metformin

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Alogliptin
Sponsor:Tecnimede-Sociedade Tecnico-Medicinal S.A.

Contact Research Centre

Ocular myasthenia

Not yet recruiting

Phase 3 Open‑Label Extension Study of Long‑Term Safety and Efficacy of Rozanolixizumab in Adults with Ocular Myasthenia Gravis

Registered drugNo placebo

Phase 3 Open‑Label Extension Study of Long‑Term Safety and Efficacy of Rozanolixizumab in Adults with Ocular Myasthenia Gravis

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Rozanolixizumab
Sponsor:UCB Biopharma

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Ranica

What the registry says about research in the country

01 Glomerulonephritis Studies

Innovative research focusing on membranoproliferative glomerulonephritis and related conditions, evaluating novel therapeutic approaches including iptacopan and pegcetacoplan for treating various forms of kidney inflammation.

IC-MPGN Treatment Evaluation
C3 Glomerulopathy Research
Post-Transplant Recurrence Studies

Multiple trials aim to reduce proteinuria and improve long-term kidney function outcomes.

02 Nephropathy Research

Comprehensive studies examining treatments for IgA Nephropathy and membranous nephropathy, including investigations of sparsentan and specialized antibody therapies for patients resistant to conventional treatments.

Primary Membranous Nephropathy
IgA Nephropathy Interventions
Antibody-Based Treatments

Focus on proteinuria reduction and preservation of renal function in various nephropathy types.

03 Chronic Kidney Disease

Advanced research into non-diabetic chronic kidney disease, exploring new therapeutic options including finerenone and investigating treatments for complications like hyperkalemia.

Disease Progression Prevention
Hyperkalemia Management
Long-term Kidney Function

Studies aim to delay disease progression and improve standard of care outcomes.

Back to Italy All countries